Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Orforglipron vs Retatrutide: Orforglipron has the stronger overall evidence (5.5 vs 5.5/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Orforglipron wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Orforglipron and Retatrutide have evidence — compare verdict strength side-by-side.
INVESTIGATIONAL — no approved consumer dose. In trials, once-daily oral orforglipron was titrated up to 36 mg (some phase-2 cohorts to 45 mg) with gradual dose escalation to limit GI side effects. Not for self-administration; only appropriate within a clinical trial or, if/when approved, under a prescribing clinician.
any
Oral tablet (investigational)
Investigational — NO approved dose. Phase-2 trials used once-weekly subcutaneous injection with stepwise escalation (e.g. start 2 mg) up to 8-12 mg maintenance. There is no approved regimen; do not self-dose an unapproved drug.
once-weekly
Once-weekly subcutaneous injection (investigational only)
Weeks to months
Months (titrated)
Throughout use
Especially during dose escalation
Progressive over 24-48 weeks
By 24 weeks
By 24-36 weeks
Especially during dose escalation
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1).
N Engl J Med (2025) · Rct · n=3127
Phase-3 multinational double-blind RCT in 3,127 adults with obesity WITHOUT diabetes; once-daily oral orforglipron 6/12/36 mg vs placebo for 72 weeks
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1).
N Engl J Med (2025) · Rct · n=559
Phase-3 double-blind RCT in 559 adults with early type 2 diabetes managed by diet/exercise; once-daily oral orforglipron 3/12/36 mg vs placebo for 40 weeks
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
Lancet (2026) · Rct · n=962
Phase-3 non-inferiority RCT (n=962) in type 2 diabetes inadequately controlled on metformin; once-daily oral orforglipron 3/12/36 mg vs dapagliflozin 10 mg over 40 weeks
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
N Engl J Med (2023) · Rct · n=338
Phase-2, double-blind, randomized, placebo-controlled trial in 338 adults with obesity (or overweight + a weight-related condition), once-weekly subcutaneous retatrutide 1-12 mg vs placebo for 48 weeks
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Lancet (2023) · Rct · n=281
Phase-2, double-blind, double-dummy, placebo- and active-comparator (1.5 mg dulaglutide)-controlled trial in 281 adults with type 2 diabetes, once-weekly retatrutide 0.5-12 mg over 36 weeks
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Nat Med (2024) · Rct · n=98
Phase-2a, randomized, double-blind, placebo-controlled MASLD substudy (n=98) of the obesity trial, in participants with ≥10% liver fat, once-weekly retatrutide 1-12 mg vs placebo
Orforglipron has a higher evidence score (5.5/10 vs 5.5/10) and wins in 1 of 3 categories.
For manage blood sugar, Orforglipron has a higher relevance score (70 vs 58).
No known interactions between Orforglipron and Retatrutide have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.